Fennec to Present at the 2019 Cantor Global Healthcare Conference on October 4, 2019
A live audio webcast of the presentation will be available on the investor relations section of Fennec’s website at http://investors.fennecpharma.com/events-and-presentations/events. A replay of the presentation will also be available and archived for 90 days.
About PEDMARK™ (Sodium Thiosulfate (STS))
Cisplatin and other platinum compounds are essential chemotherapeutic components for many pediatric malignancies. Unfortunately, platinum-based therapies cause ototoxicity in many patients, and are particularly harmful to the survivors of pediatric cancer.
STS has been studied by cooperative groups in two Phase 3 clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. Both studies are completed. The COG ACCL0431 protocol enrolled one of five childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including newly diagnosed hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.
For further information, please contact:
Chief Executive Officer
T: (919) 636-5144
Source: Fennec Pharmaceuticals Inc.